de la Cruz, C.G.; Thomas, L.; Mata-MartÃn, C.; González, I.; LLerena, A.; Peñas-Lledó, E.M.
Pharmacogenomics of CYP2D6, CYP2C19, CYP2C9, and Clinical Determinants of Fluoxetine–Norfluoxetine Pharmacokinetics in Real-World Clinical Conditions. Pharmaceutics 2026, 18, 41.
https://doi.org/10.3390/pharmaceutics18010041
AMA Style
de la Cruz CG, Thomas L, Mata-MartÃn C, González I, LLerena A, Peñas-Lledó EM.
Pharmacogenomics of CYP2D6, CYP2C19, CYP2C9, and Clinical Determinants of Fluoxetine–Norfluoxetine Pharmacokinetics in Real-World Clinical Conditions. Pharmaceutics. 2026; 18(1):41.
https://doi.org/10.3390/pharmaceutics18010041
Chicago/Turabian Style
de la Cruz, Carla González, Levin Thomas, Carmen Mata-MartÃn, Idian González, Adrián LLerena, and Eva M. Peñas-Lledó.
2026. "Pharmacogenomics of CYP2D6, CYP2C19, CYP2C9, and Clinical Determinants of Fluoxetine–Norfluoxetine Pharmacokinetics in Real-World Clinical Conditions" Pharmaceutics 18, no. 1: 41.
https://doi.org/10.3390/pharmaceutics18010041
APA Style
de la Cruz, C. G., Thomas, L., Mata-MartÃn, C., González, I., LLerena, A., & Peñas-Lledó, E. M.
(2026). Pharmacogenomics of CYP2D6, CYP2C19, CYP2C9, and Clinical Determinants of Fluoxetine–Norfluoxetine Pharmacokinetics in Real-World Clinical Conditions. Pharmaceutics, 18(1), 41.
https://doi.org/10.3390/pharmaceutics18010041
